Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Cyclica Launches First-of-its-kind Ligand Design<sup>TM</sup>

Cyclica, a biotechnology company announced its novel, first-in-class drug design technology, Ligand DesignTM at the Collision Conference in Toronto.

Ligand DesignTM provides scientists with an opportunity to generate novel drug-like compounds by combining powerful methods for molecule generation, ADMET prediction, and high-throughput Ligand-protein interaction prediction.

Ligand design is a classical computational drug design approach, like virtual screening, focus on a single protein target. The phenomenon of one drug acting on multiple proteins in the body, or a drug’s pharmacokinetic properties, describes how a drug is absorbed and processed by the body.

Ligand Design's single target focuses on a drug’s polypharmacology and explores synthetically accessible chemical space to de novo design small molecules against a collection of targets and anti-targets, while simultaneously selecting for physicochemical and ADMET properties.

Ligand DesignTM has the ability to transform research and discovery processes and augment the capabilities of scientists to rapidly design drugs with greater precision and efficacy.

The novel platform is showing promising results in the drug discovery. To date, several novel agents have been synthesized and tested successfully for activity in multiple disease areas.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024